A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Completed · Phase 3
Conditions studied: Generalized Lipodystrophy
In brief
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switching from treatment with metreleptin. The study is looking at several other research questions, including: * What side effects may happen from taking mibavademab * How much mibavademab is in the blood at different times * Whether the body makes antibodies against mibavademab (which could make mibavademab less effective or could lead to side effects)
Key facts
- Study ID
- NCT06548100
- Run by
- Regeneron Pharmaceuticals
- People needed
- 9
- Starts
- 2024-12-16
- Expected to finish
- 2026-07-09
- Last updated by the study team
- 2026-07-29
Who can join
Age: 2 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Institutes of Health — Bethesda, Maryland, United States
- University of Michigan — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.